rethinkPeptides Search
Menu
Study breakdown

GLP-1 Drugs and Suicide Risk: Meta-Analysis Finds No Significant Association

Meta AnalysisStrong evidence
The takeaway

Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing further reassurance on the psychiatric safety of these widely used drugs.

Key finding

Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing fu

What the researchers found

Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing further reassurance on the psychiatric safety of these widely used drugs.

Why it matters

This finding has implications for the millions of patients using or considering peptide-based therapies.

The numbers in context

Searched 6 databases from first published article through October 2024. Found no statistically significant increase in suicidal ideation or suicide completion.

How the study worked

Clinical or preclinical study with methodology detailed in the full publication.

Who was studied

Adults with diabetes or obesity using GLP-1 receptor agonists

What this study cannot tell us

Study-specific limitations are discussed in the full publication. As with all research, findings should be interpreted in the context of study design and population.

How to read the evidence

Evidence grade assessment based on study design and methodology detailed in the full publication.

When this study was published

Published in 2025. Reflects current state of peptide therapeutic research.

The bigger picture

This study adds to the rapidly expanding evidence base for peptide-based therapeutics across multiple medical specialties.

Questions still open

  • What are the long-term implications of these findings?
  • How do these results compare to other studies in this area?
  • What further research is needed to confirm and extend these findings?

Common questions

What does this study mean for patients?
Meta-analysis of GLP-1 agonists and suicidal ideation finds no significant association, providing further reassurance on the psychiatric safety of these widely used drugs.
How reliable are these findings?
The evidence level depends on study design. Clinical trials provide stronger evidence than case reports. Consult the full publication and discuss with your healthcare provider.

Read the original research

Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.

Medicine, 104(49), e46173

Citation

Alansari, Amal Omar; Alharbi, Ahlam Saleem; Alshehri, Khaled Mohammad; Alhabib, Ali Tareq; Alsalmi, Bodour Saleh; Almosfer, Waleed Abdulaziz; AlAjlan, Fadiyah Abdullah; Alharbi, Abeer Abdullah; Alzahrani, Basmah Saleh; Alamer, Bader; Alatawi, Amirah M. (2025). Assessing the shadows: A meta-analysis of GLP-1 agonists and suicidal ideation.. Medicine, 104(49), e46173. https://doi.org/10.1097/MD.0000000000046173